Licensing · Latin America · Announced 11 May 2022

Shanghai Henlius Biotech → Eurofarma

Henlius licensed Brazil's Eurofarma to develop, make and sell its rituximab, trastuzumab and bevacizumab biosimilars in 16 Latin American countries for up to US$50.5 million, including US$4.5 million upfront.

Parties: Shanghai Henlius Biotech (China) → Eurofarma (Brazil)

Deal type
Licensing
Value
$50.5m
Territory
16 Latin American countries; exclusive by product (incl. Mexico, Chile, Argentina), semi-exclusive in Brazil
Therapeutic area
Oncology
Assets
HANLIKANG (rituximab); HANQUYOU (trastuzumab); HANBEITAI (bevacizumab)
Announced
11 May 2022

Our analysis

Why this matters

Shanghai Henlius Biotech and Eurofarma signed a license and collaboration agreement, announced on 11 May 2022, for development, manufacturing and commercialisation of three Henlius biosimilars in 16 Latin American countries: HANLIKANG (rituximab), HANQUYOU (trastuzumab) and HANBEITAI (bevacizumab). The deal is worth up to US$50.5 million, including US$4.5 million upfront.

Rights are exclusive by product: rituximab in 12 countries, trastuzumab in 11 and bevacizumab in 15, with examples including Mexico, Chile, Argentina, Guatemala, Panama and Ecuador, and semi-exclusive in Brazil.

The full analysis is free to read with a work email on this page.

Source: Henlius press release

More deals involving Shanghai Henlius Biotech or Eurofarma

Latest deals

All Latin America deals → · All licensing deals → · Browse all emerging-market pharma deals →